
EU Approves TEVIMBRA+Chemo for First-Line Nasopharyngeal Cancer
BeOne, a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with metastatic…












